Takafumi Yanagisawa

List of Publications by Year
in descending order

28	265	1039880 9	1125617 13
papers	citations	h-index	g-index

29	29	29	111
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	En Bloc Resection for Bladder Tumors: An Updated Systematic Review and Meta-Analysis of Its Differential Effect on Safety, Recurrence and Histopathology. Journal of Urology, 2022, 207, 754-768.	0.2	26
2	Feasibility and accuracy of pathological diagnosis in enâ€bloc transurethral resection specimens versus conventional transurethral resection specimens of bladder tumour: evaluation with pT1 substaging by 10 pathologists. Histopathology, 2021, 78, 943-950.	1.6	21
3	Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis. International Journal of Clinical Oncology, 2022, 27, 59-71.	1.0	19
4	Vertical Lamina Propria Invasion Diagnosed by En Bloc Transurethral Resection is a Significant Predictor of Progression for pT1 Bladder Cancer. Journal of Urology, 2021, 205, 1622-1628.	0.2	16
5	Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis. European Urology, 2022, 82, 82-96.	0.9	15
6	Differential efficacy of ablation therapy versus partial nephrectomy between clinical T1a and T1b renal tumors: A systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 315-330.	0.8	15
7	Clinical Significance of Horizontal and Vertical Margin of En Bloc Resection for Nonmuscle Invasive Bladder Cancer. Journal of Urology, 2021, 206, 252-259.	0.2	13
8	The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: A systematic review and meta-analysis. International Immunopharmacology, 2022, 108, 108720.	1.7	13
9	Do we need repeat <scp>transurethral resection</scp> after en bloc resection for <scp>pathological T1</scp> bladder cancer?. BJU International, 2023, 131, 190-197.	1.3	13
10	Functional and oncological outcome of percutaneous cryoablation versus laparoscopic partial nephrectomy for clinical T1 renal tumors: A propensity score-matched analysis. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 938.e1-938.e7.	0.8	11
11	Comparison of Clinicopathologic and Oncological Outcomes Between Transurethral En Bloc Resection and Conventional Transurethral Resection of Bladder Tumor: A Systematic Review, Meta-Analysis, and Network Meta-Analysis with Focus on Different Energy Sources. Journal of Endourology, 2022, 36, 535-547.	1.1	11
12	Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes. Critical Reviews in Oncology/Hematology, 2022, 169, 103570.	2.0	11
13	Reassessment of the Efficacy of Carboplatin for Metastatic Urothelial Carcinoma in the Era of Immunotherapy: A Systematic Review and Meta-analysis. European Urology Focus, 2022, 8, 1687-1695.	1.6	10
14	Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis. Immunotherapy, 2022, 14, 709-725.	1.0	10
15	Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for highâ€risk metastatic hormoneâ€sensitive prostate cancer. Prostate, 2022, 82, 3-12.	1.2	9
16	Performance of Indocyanine Green Fluorescence for Detecting Lymph Node Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis. Clinical Genitourinary Cancer, 2021, 19, 466.e1-466.e9.	0.9	9
17	Accuracy of SelectMDx compared to mpMRI in the diagnosis of prostate cancer: a systematic review and diagnostic meta-analysis. Prostate Cancer and Prostatic Diseases, 2022, 25, 187-198.	2.0	7
18	Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy. European Urology Oncology, 2022, 5, 120-124.	2.6	6

#	Article	IF	Citations
19	Influence of steep Trendelenburg position on postoperative complications: a systematic review and meta-analysis. Journal of Robotic Surgery, 2022, 16, 1233-1247.	1.0	6
20	Evaluation of the Predictive Role of Blood-Based Biomarkers in the Context of Suspicious Prostate MRI in Patients Undergoing Prostate Biopsy. Journal of Personalized Medicine, 2021, 11, 1231.	1.1	5
21	Residue and recurrence in percutaneous cryoablation for cT1 renal tumor: Clinical utility and feasibility of salvage cryoablation with iodized oil marking. International Journal of Urology, 2022, 29, 472-474.	0.5	4
22	Circulating Tumour DNA Is a Strong Predictor of Outcomes in Patients Treated with Systemic Therapy for Urothelial Carcinoma. European Urology Focus, 2022, 8, 1683-1686.	1.6	4
23	Impact of Dose-Effect in Smoking on the Effectiveness of Pembrolizumab in Patients with Metastatic Urothelial Carcinoma. Targeted Oncology, 2021, 16, 189-196.	1.7	3
24	Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis. World Journal of Urology, 0, , .	1.2	3
25	Quality indicators for the management of muscle-invasive bladder cancer in the perioperative setting of radical cystectomy: a narrative review. Translational Cancer Research, 2022, 11, 908-917.	0.4	2
26	Values of alkaline phosphatase at the diagnosis of castration resistance and response to primary androgen deprivation therapy as predictors of subsequent metastasis in non-metastatic castration-resistant prostate cancer. International Journal of Clinical Oncology, 2020, 25, 479-485.	1.0	1
27	Effect of upfront intensive therapy on oncological outcomes in older patients with high tumor burden metastatic castrationâ€sensitive prostate cancer: A multicenter retrospective study. Prostate, 0, , .	1.2	1
28	Does castration status affect docetaxelâ€related adverse events? :Identification of risk factors for docetaxelâ€related adverse events in metastatic prostate cancer. Prostate, 0, , .	1.2	1